USH3A Inhibitors
USH3A inhibitors encompass a diverse array of chemicals with distinct mechanisms targeting various signaling pathways implicated in USH3A-mediated cellular processes. H-89, a PKA inhibitor, modulates cAMP-dependent signaling, indirectly influencing USH3A by altering downstream effectors. Sorafenib, a multi-kinase inhibitor, disrupts RAF/MEK/ERK signaling, impacting USH3A-related phosphorylation cascades. PP2, a Src family kinase inhibitor, modulates tyrosine kinase activity, perturbing cellular processes governed by USH3A-related pathways influenced by Src family kinases. Moreover, BIX 02189, a MEK5 inhibitor, disrupts ERK5 signaling, altering phosphorylation cascades and gene expression patterns associated with USH3A. SB 203580, a p38 MAPK inhibitor, modulates stress-activated signaling, perturbing cellular responses governed by USH3A-related pathways influenced by p38 MAPK. Rapamycin, an mTOR inhibitor, disrupts mTOR signaling, impacting cellular processes associated with mTOR-mediated regulation and USH3A-related pathways.
Additionally, SP600125, a JNK inhibitor, disrupts JNK signaling, influencing cellular responses governed by USH3A-related pathways influenced by JNK. Wortmannin, a PI3K inhibitor, modulates PI3K/Akt signaling, altering cellular processes associated with PI3K/Akt-mediated regulation and USH3A-related pathways. VX-11e, a CDK inhibitor, disrupts the cell cycle, perturbing cellular processes associated with USH3A-related pathways influenced by CDKs. Furthermore, AG-490, a JAK2 inhibitor, modulates JAK/STAT signaling, indirectly influencing USH3A by altering cellular processes associated with JAK/STAT-mediated regulation. Trametinib and U0126, MEK inhibitors, disrupt the MEK/ERK signaling pathway, altering phosphorylation cascades and cellular processes associated with USH3A. This comprehensive selection of inhibitors provides valuable tools for dissecting the intricate regulatory networks involving USH3A, paving the way for precise experimental investigations.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, disrupts RAF/MEK/ERK signaling. Its impact on this pathway indirectly influences USH3A by altering the phosphorylation cascades that contribute to cellular processes associated with USH3A regulation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2, a Src family kinase inhibitor, modulates tyrosine kinase activity. Its influence on Src-mediated signaling indirectly affects USH3A by perturbing cellular processes governed by USH3A-related pathways influenced by Src family kinases. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $220.00 $378.00 | 5 | |
BIX 02189, a MEK5 inhibitor, disrupts the ERK5 signaling pathway. Its impact on ERK5-mediated processes indirectly influences USH3A by altering the phosphorylation cascades and gene expression patterns associated with cellular processes regulated by USH3A. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580, a p38 MAPK inhibitor, modulates stress-activated signaling. Its influence on the p38 MAPK pathway indirectly affects USH3A by perturbing cellular processes associated with stress responses and the USH3A-related pathways influenced by p38 MAPK. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, disrupts the mTOR signaling pathway. Its impact on this pathway indirectly influences USH3A by altering cellular processes associated with mTOR-mediated regulation, contributing to the modulation of USH3A-related pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, disrupts JNK signaling pathways. Its influence on JNK-mediated processes indirectly affects USH3A by perturbing cellular responses governed by USH3A-related pathways influenced by JNK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts the PI3K/Akt signaling pathway. Its impact on this pathway indirectly influences USH3A by altering cellular processes associated with PI3K/Akt-mediated regulation, contributing to the modulation of USH3A-related pathways. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e, a CDK inhibitor, disrupts cell cycle regulation. Its influence on CDK-mediated pathways indirectly affects USH3A by perturbing the cell cycle, contributing to the modulation of cellular processes associated with USH3A-related pathways influenced by CDKs. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490, a JAK2 inhibitor, modulates JAK/STAT signaling. Its impact on this pathway indirectly influences USH3A by altering cellular processes associated with JAK/STAT-mediated regulation, contributing to the modulation of USH3A-related pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, a MEK inhibitor, disrupts the MEK/ERK signaling pathway. Its influence on this pathway indirectly affects USH3A by altering the phosphorylation cascades that contribute to cellular processes associated with USH3A regulation. | ||||||